Genelux Corporation (GNLX)
Nasdaq: GNLX · Pharmaceutical Preparations · Westlake Village, CA · filing with the SEC since 2003
Filings
125 filings since 2017 beside 227 insider forms · Non-accelerated filer and smaller reporting company and emerging growth company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company and emerging growth company
10-Q
Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by Nov 14, 2026
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. The proxy statement was last filed Apr 29, 2026.
Filings a yearinsider forms included
11519143815153
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 5 times in the last 36 months, the newest Jan 2, 2026.SEC letters: 2 in the last 36 months, the newest Feb 8, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Jan 5, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Sep 3, 2025
8-K items 5.02, 5.07
Officer or director change; Shareholder vote · Current report
Aug 27, 2025
Mar 25, 2025
8-K items 2.02, 7.01, 8.01, 9.01
Results released; Investor disclosure (Regulation FD); Other event · Current report
40 of 125 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.